SBR759 + Sevelamer HCl + SBR759 + Sevelamer HCl
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
Conditions
Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
Trial Timeline
Jul 1, 2008 → —
NCT ID
NCT00704483About SBR759 + Sevelamer HCl + SBR759 + Sevelamer HCl
SBR759 + Sevelamer HCl + SBR759 + Sevelamer HCl is a phase 2 stage product being developed by Novartis for Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy. The current trial status is completed. This product is registered under clinical trial identifier NCT00704483. Target conditions include Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00704483 | Phase 2 | Completed |
Competing Products
20 competing products in Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy